1
|
Abi Nahed R, Safwan-Zaiter H, Gemy K, Lyko C, Boudaud M, Desseux M, Marquette C, Barjat T, Alfaidy N, Benharouga M. The Multifaceted Functions of Prion Protein (PrP C) in Cancer. Cancers (Basel) 2023; 15:4982. [PMID: 37894349 PMCID: PMC10605613 DOI: 10.3390/cancers15204982] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 09/23/2023] [Accepted: 10/11/2023] [Indexed: 10/29/2023] Open
Abstract
The cellular prion protein (PrPC) is a glycoprotein anchored to the cell surface by glycosylphosphatidylinositol (GPI). PrPC is expressed both in the brain and in peripheral tissues. Investigations on PrPC's functions revealed its direct involvement in neurodegenerative and prion diseases, as well as in various physiological processes such as anti-oxidative functions, copper homeostasis, trans-membrane signaling, and cell adhesion. Recent findings have revealed the ectopic expression of PrPC in various cancers including gastric, melanoma, breast, colorectal, pancreatic, as well as rare cancers, where PrPC promotes cellular migration and invasion, tumor growth, and metastasis. Through its downstream signaling, PrPC has also been reported to be involved in resistance to chemotherapy and tumor cell apoptosis. This review summarizes the variance of expression of PrPC in different types of cancers and discusses its roles in their development and progression, as well as its use as a potential target to treat such cancers.
Collapse
Affiliation(s)
- Roland Abi Nahed
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Hasan Safwan-Zaiter
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Kevin Gemy
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Camille Lyko
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Mélanie Boudaud
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Morgane Desseux
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Christel Marquette
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Tiphaine Barjat
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Nadia Alfaidy
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| | - Mohamed Benharouga
- U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France; (R.A.N.); (H.S.-Z.); (K.G.); (C.L.); (M.B.); (M.D.); (C.M.); (T.B.); (N.A.)
- Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
- University of Grenoble Alpes (UGA), F-38058 Grenoble, France
| |
Collapse
|
2
|
Li J, Li S, Yu S, Yang J, Ke J, Li H, Chen H, Lu M, Sy MS, Gao Z, Li C. Persistent ER stress causes GPI anchor deficit to convert a GPI-anchored prion protein into pro-PrP via the ATF6-miR449c-5p-PIGV axis. J Biol Chem 2023; 299:104982. [PMID: 37390992 PMCID: PMC10388210 DOI: 10.1016/j.jbc.2023.104982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 06/21/2023] [Accepted: 06/22/2023] [Indexed: 07/02/2023] Open
Abstract
Endoplasmic reticulum (ER) stress and unfolded protein response are cells' survival strategies to thwart disruption of proteostasis. Tumor cells are continuously being challenged by ER stress. The prion protein, PrP, normally a glycosylphosphatidylinositol (GPI)-anchored protein exists as a pro-PrP retaining its GPI-peptide signal sequence in human pancreatic ductal cell adenocarcinoma (PDAC). Higher abundance of pro-PrP indicates poorer prognosis in PDAC patients. The reason why PDAC cells express pro-PrP is unknown. Here, we report that persistent ER stress causes conversion of GPI-anchored PrP to pro-PrP via a conserved ATF6-miRNA449c-5p-PIGV axis. Mouse neurons and AsPC-1, a PDAC cell line, express GPI-anchored PrP. However, continuous culture of these cells with the ER stress inducers thapsigargin or brefeldin A results in the conversion of a GPI-anchored PrP to pro-PrP. Such a conversion is reversible; removal of the inducers allows the cells to re-express a GPI-anchored PrP. Mechanistically, persistent ER stress increases the abundance of an active ATF6, which increases the level of miRNA449c-5p (miR449c-5p). By binding the mRNA of PIGV at its 3'-UTRs, miR449c-5p suppresses the level of PIGV, a mannosyltransferase pivotal in the synthesis of the GPI anchor. Reduction of PIGV leads to disruption of the GPI anchor assembly, causing pro-PrP accumulation and enhancing cancer cell migration and invasion. The importance of ATF6-miR449c-5p-PIGV axis is recapitulated in PDAC biopsies as the higher levels of ATF6 and miR449c-5p and lower levels of PIGV are markers of poorer outcome for patients with PDAC. Drugs targeting this axis may prevent PDAC progression.
Collapse
Affiliation(s)
- JingFeng Li
- Wuhan Institute of Virology, Chinese Academy of Sciences, State Key Laboratory of Virology, Wuhan, China; University of Chinese Academy of Sciences, Beijing, China
| | - SaSa Li
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China
| | - ShuPei Yu
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China
| | - Jie Yang
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China
| | - JingRu Ke
- Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Huan Li
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China
| | - Heng Chen
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China
| | - MingJian Lu
- Department of Interventional Radiology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
| | - Man-Sun Sy
- Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
| | - ZhenXing Gao
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
| | - Chaoyang Li
- Wuhan Institute of Virology, Chinese Academy of Sciences, State Key Laboratory of Virology, Wuhan, China; University of Chinese Academy of Sciences, Beijing, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou, China.
| |
Collapse
|
3
|
Cha S, Sin MJ, Kim MJ, Kim HJ, Kim YS, Choi EK, Kim MY. Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development. Biomolecules 2021; 11:biom11020285. [PMID: 33671884 PMCID: PMC7918983 DOI: 10.3390/biom11020285] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 02/10/2021] [Accepted: 02/12/2021] [Indexed: 12/15/2022] Open
Abstract
The cellular prion protein (PrPC) is a cell surface glycoprotein expressed in many cell types that plays an important role in normal cellular processes. However, an increase in PrPC expression has been associated with a variety of human cancers, where it may be involved in resistance to the proliferation and metastasis of cancer cells. PrP-deficient (Prnp0/0) and PrP-overexpressing (Tga20) mice were studied to evaluate the role of PrPC in the invasion and metastasis of cancer. Tga20 mice, with increased PrPC, died more quickly from lung cancer than did the Prnp0/0 mice, and this effect was associated with increased transforming growth factor-beta (TGF-β) and programmed death ligand-1 (PD-L1), which are important for the development and function of regulatory T (Treg) cells. The number of FoxP3+CD25+ Treg cells was increased in Tga20 mice compared to Prnp0/0 mice, but there was no significant difference in either natural killer or cytotoxic T cell numbers. In addition, mice infected with the ME7 scrapie strain had decreased numbers of Treg cells and decreased expression of TGF-β and PD-L1. These results suggest that PrPC plays an important role in invasion and metastasis of cancer cells by inducing Treg cells through upregulation of TGF-β and PD-L1 expression.
Collapse
Affiliation(s)
- Seunghwa Cha
- School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea; (S.C.); (M.-J.S.)
| | - Mi-Ji Sin
- School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea; (S.C.); (M.-J.S.)
| | - Mo-Jong Kim
- Ilsong Institute of Life Science, Hallym University, Anyang 14066, Korea; (M.-J.K.); (H.-J.K.); (Y.-S.K.)
- Department of Biomedical Gerontology, Graduate School of Hallym University, Chuncheon 24252, Korea
| | - Hee-Jun Kim
- Ilsong Institute of Life Science, Hallym University, Anyang 14066, Korea; (M.-J.K.); (H.-J.K.); (Y.-S.K.)
| | - Yong-Sun Kim
- Ilsong Institute of Life Science, Hallym University, Anyang 14066, Korea; (M.-J.K.); (H.-J.K.); (Y.-S.K.)
| | - Eun-Kyoung Choi
- Ilsong Institute of Life Science, Hallym University, Anyang 14066, Korea; (M.-J.K.); (H.-J.K.); (Y.-S.K.)
- Department of Biomedical Gerontology, Graduate School of Hallym University, Chuncheon 24252, Korea
- Correspondence: (E.-K.C.); (M.-Y.K.)
| | - Mi-Yeon Kim
- School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea; (S.C.); (M.-J.S.)
- Correspondence: (E.-K.C.); (M.-Y.K.)
| |
Collapse
|
4
|
The Role of Cellular Prion Protein in Promoting Stemness and Differentiation in Cancer. Cancers (Basel) 2021; 13:cancers13020170. [PMID: 33418999 PMCID: PMC7825291 DOI: 10.3390/cancers13020170] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 12/31/2020] [Accepted: 01/03/2021] [Indexed: 02/05/2023] Open
Abstract
Simple Summary Aside from its well-established role in prion disorders, in the last decades the significance of cellular prion protein (PrPC) expression in human cancers has attracted great attention. An extensive body of work provided evidence that PrPC contributes to tumorigenesis by regulating tumor growth, differentiation, and resistance to conventional therapies. In particular, PrPC over-expression has been related to the acquisition of a malignant phenotype of cancer stem cells (CSCs) in a variety of solid tumors, encompassing pancreatic ductal adenocarcinoma, osteosarcoma, breast, gastric, and colorectal cancers, and primary brain tumors as well. According to consensus, increased levels of PrPC endow CSCs with self-renewal, proliferative, migratory, and invasive capacities, along with increased resistance to anti-cancer agents. In addition, increasing evidence demonstrates that PrPc also participates in multi-protein complexes to modulate the oncogenic properties of CSCs, thus sustaining tumorigenesis. Therefore, strategies aimed at targeting PrPC and/or PrPC-organized complexes could be a promising approach for anti-cancer therapy. Abstract Cellular prion protein (PrPC) is seminal to modulate a variety of baseline cell functions to grant homeostasis. The classic role of such a protein was defined as a chaperone-like molecule being able to rescue cell survival. Nonetheless, PrPC also represents the precursor of the deleterious misfolded variant known as scrapie prion protein (PrPSc). This variant is detrimental in a variety of prion disorders. This multi-faceted role of PrP is greatly increased by recent findings showing how PrPC in its folded conformation may foster tumor progression by acting at multiple levels. The present review focuses on such a cancer-promoting effect. The manuscript analyzes recent findings on the occurrence of PrPC in various cancers and discusses the multiple effects, which sustain cancer progression. Within this frame, the effects of PrPC on stemness and differentiation are discussed. A special emphasis is provided on the spreading of PrPC and the epigenetic effects, which are induced in neighboring cells to activate cancer-related genes. These detrimental effects are further discussed in relation to the aberrancy of its physiological and beneficial role on cell homeostasis. A specific paragraph is dedicated to the role of PrPC beyond its effects in the biology of cancer to represent a potential biomarker in the follow up of patients following surgical resection.
Collapse
|
5
|
Zhang T, Chen Y, Lin W, Zheng J, Liu Y, Zou J, Cai J, Chen Y, Li Z, Chen Y. Prognostic and Immune-Infiltrate Significance of miR-222-3p and Its Target Genes in Thyroid Cancer. Front Genet 2021; 12:710412. [PMID: 34737762 PMCID: PMC8562566 DOI: 10.3389/fgene.2021.710412] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Accepted: 10/04/2021] [Indexed: 02/05/2023] Open
Abstract
Thyroid cancer (THCA) is a common endocrine malignancy. With increasing incidence and low mortality, balancing the therapeutic approach is an inevitable issue. This study aimed to confirm the role of miR-222-3p and its target genes in THCA survival and immune infiltration. From different expression analyses based on the GEO and TCGA databases, we predicted and subsequently identified the key target genes of miR-222-3p. We then explored the expression, enrichment, pairwise correlation, protein expression, survival analysis, principal component analysis, and immune significance of the critical genes using bioinformatics analysis. The present study demonstrated that NEGR1, NTNG1, XPNPEP2, NTNG2, CD109, OPCML, and PRND are critical genes. The miR-222-3p was highly expressed, probably leading to low NEGR1 and high PRND expression in THCA tissues. Low NEGR1 expression indicated favorable prognosis in THCA patients, and high PRND expression indicated poor prognosis. Seven critical genes were significantly related to gender, age, race, tumor stage, and lymph node metastasis. In addition, the seven-gene biomarker exhibited a certain diagnostic value. Finally, CD109 expression was closely correlated with immune cells, especially B cells and CD4+ T cells. The miR-222-3p and its critical target genes could be promising biomarkers for the prognosis of THCA and may emerge as key regulators of immune infiltration in THCA.
Collapse
Affiliation(s)
- Taofeng Zhang
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Yihuan Chen
- Department of Ultrasound in Obstetrics and Gynecology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Weixun Lin
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Jiehua Zheng
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- Department of Breast Disease Research Center, Medical Research Institute of Shantou Doctoral Association, Shantou, China
| | - Yiyuan Liu
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- Department of Breast Disease Research Center, Medical Research Institute of Shantou Doctoral Association, Shantou, China
| | - Juan Zou
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- Department of Breast Disease Research Center, Medical Research Institute of Shantou Doctoral Association, Shantou, China
| | - Jiehui Cai
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- Department of Breast Disease Research Center, Medical Research Institute of Shantou Doctoral Association, Shantou, China
| | - Yaokun Chen
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- Department of Breast Disease Research Center, Medical Research Institute of Shantou Doctoral Association, Shantou, China
| | - Zhiyang Li
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- *Correspondence: Zhiyang Li, ; Yexi Chen,
| | - Yexi Chen
- Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China
- *Correspondence: Zhiyang Li, ; Yexi Chen,
| |
Collapse
|
6
|
Colini Baldeschi A, Vanni S, Zattoni M, Legname G. Novel regulators of PrP C expression as potential therapeutic targets in prion diseases. Expert Opin Ther Targets 2020; 24:759-776. [PMID: 32631090 DOI: 10.1080/14728222.2020.1782384] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Prion diseases are rare and fatal neurodegenerative disorders. The key molecular event in these disorders is the misfolding of the physiological form of the cellular prion protein, PrPC, leading to the accumulation of a pathological isoform, PrPSc, with unique features. Both isoforms share the same primary sequence, lacking detectable differences in posttranslational modification, a major hurdle for their biochemical or biophysical independent characterization. The mechanism underlying the conversion of PrPC to PrPSc is not completely understood, so finding an effective therapy to cure prion disorders is extremely challenging. AREAS COVERED This review discusses the strategies for decreasing prion replication and throws a spotlight on the relevance of PrPC in the prion accumulation process. EXPERT OPINION PrPC is the key substrate for prion pathology; hence, the most promising therapeutic approach appears to be the targeting of PrPC to block the production of the infectious isoform. The use of RNA interference and antisense oligonucleotide technologies may offer opportunities for treatment because of their success in clinical trials for other neurodegenerative diseases.
Collapse
Affiliation(s)
- Arianna Colini Baldeschi
- Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore Di Studi Avanzati (SISSA) , Trieste, Italy
| | - Silvia Vanni
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per Lo Studio E La Cura Dei Tumori (IRST) IRCCS , Meldola, Italy
| | - Marco Zattoni
- Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore Di Studi Avanzati (SISSA) , Trieste, Italy
| | - Giuseppe Legname
- Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore Di Studi Avanzati (SISSA) , Trieste, Italy
| |
Collapse
|
7
|
Sahar T, Nigam A, Anjum S, Waziri F, Biswas S, Jain SK, Wajid S. Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma. Anticancer Agents Med Chem 2020; 19:1293-1312. [PMID: 30727917 DOI: 10.2174/1871520619666190206143523] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 01/22/2019] [Accepted: 01/26/2019] [Indexed: 12/18/2022]
Abstract
BACKGROUND Recent advances in proteomics present enormous opportunities to discover proteome related disparities and thus understanding the molecular mechanisms related to a disease. Uterine leiomyoma is a benign monoclonal tumor, located in the pelvic region, and affecting 40% of reproductive aged female. OBJECTIVE Identification and characterization of the differentially expressed proteins associated with leiomyogenesis by comparing uterine leiomyoma and normal myometrium. METHODS Paired samples of uterine leiomyoma and adjacent myometrium retrieved from twenty-five females suffering from uterine leiomyoma (n=50) were submitted to two-dimensional electrophoresis (2-DE), matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and to reverse transcription polymerase chain reaction (RT-PCR). RESULTS Comparison of protein patterns revealed seven proteins with concordantly increased spot intensities in leiomyoma samples. E3 ubiquitin-protein ligase MIB2 (MIB2), Mediator of RNA polymerase II transcription subunit 10 (MED10), HIRA-interacting protein (HIRP3) and Fatty acid binding protein brain (FABP7) were found to be upregulated. While, Biogenesis of lysosome-related organelles complex 1 subunit 2 (BL1S2), Shadow of prion protein (SPRN) and RNA binding motif protein X linked like 2 (RMXL2) were found to be exclusively present in leiomyoma sample. The expression modulations of the corresponding genes were further validated which corroborated with the 2-DE result showing significant upregulation in leiomyoma. We have generated a master network showing the interactions of the experimentally identified proteins with their close neighbors and further scrutinized the network to prioritize the routes leading to cell proliferation and tumorigenesis. CONCLUSION This study highlights the importance of identified proteins as potential targets for therapeutic purpose. This work provides an insight into the mechanism underlying the overexpression of the proteins but warrants further investigations.
Collapse
Affiliation(s)
- Tahreem Sahar
- Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India
| | - Aruna Nigam
- Department of Obstetrics and Gynecology, HIMSR and HAH Centenary Hospital, Jamia Hamdard, New Delhi 110062, India
| | - Shadab Anjum
- Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India
| | - Farheen Waziri
- Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India
| | - Shipie Biswas
- Molecular Diagnostics, Genetix Biotech Asia Pvt. Ltd., New Delhi 110015, India
| | - Swatantra K Jain
- Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.,Department of Biochemistry, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi 110062, India
| | - Saima Wajid
- Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India
| |
Collapse
|
8
|
Prion Protein Family Contributes to Tumorigenesis via Multiple Pathways. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 1018:207-224. [PMID: 29052140 DOI: 10.1007/978-981-10-5765-6_13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
A wealth of evidence suggests that proteins from prion protein (PrP) family contribute to tumorigenesis in many types of cancers, including pancreatic ductal adenocarcinoma (PDAC), breast cancer, glioblastoma, colorectal cancer, gastric cancer, melanoma, etc. It is well documented that PrP is a biomarker for PDAC, breast cancer, and gastric cancer. However, the underlying mechanisms remain unclear. The major reasons for cancer cell-caused patient death are metastasis and multiple drug resistance, both of which connect to physiological functions of PrP expressing in cancer cells. PrP enhances tumorigenesis by multiple pathways. For example, PrP existed as pro-PrP in most of the PDAC cell lines, thus increasing cancer cell motility by binding to cytoskeletal protein filamin A (FLNa). Using PDAC cell lines BxPC-3 and AsPC-1 as model system, we identified that dysfunction of glycosylphosphatidylinositol (GPI) anchor synthesis machinery resulted in the biogenesis of pro-PrP. In addition, in cancer cells without FLNa expression, pro-PrP can modify cytoskeleton structure by affecting cofilin/F-actin axis, thus influencing cancer cell movement. Besides pro-PrP, we showed that GPI-anchored unglycosylated PrP can elevate cell mobility by interacting with VEGFR2, thus stimulating cell migration under serum-free condition. Besides affecting cancer cell motility, overexpressed PrP or doppel (Dpl) in cancer cells has been shown to increase cell proliferation, multiple drug resistance, and angiogenesis, thus, proteins from PrP gene family by affecting important processes via multiple pathways for cancer cell growth exacerbating tumorigenesis.
Collapse
|
9
|
Conti A, Fredolini C, Tamburro D, Magagnoli G, Zhou W, Liotta LA, Picci P, Luchini A, Benassi MS. Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas: Correlation with metastatic progression. Proteomics 2016; 16:689-97. [PMID: 26699407 DOI: 10.1002/pmic.201500164] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Revised: 10/19/2015] [Accepted: 12/16/2015] [Indexed: 12/11/2022]
Abstract
Soft tissue sarcomas (STS) are a heterogeneous group of rare tumors for which identification and validation of biological markers may improve clinical management. The fraction of low-molecular-weight (LMW) circulating proteins and fragments of proteins is a rich source of new potential biomarkers. To identify circulating biomarkers useful for STS early diagnosis and prognosis, we analyzed 53 high-grade STS sera using hydrogel core-shell nanoparticles that selectively entrap LMW proteins by size exclusion and affinity chromatography, protect them from degradation and amplify their concentration for mass spectrometry detection. Twenty-two analytes mostly involved in inflammatory and immunological response, showed a progressive increase from benign to malignant STS with a relative difference in abundance, more than 50% when compared to healthy control. 16 of these were higher in metastatic compared to non-metastatic tumors. Cox's regression analysis revealed a statistical significant association between the abundance of lactotransferrin (LTF) and complement factor H-related 5 (CFHR5) and risk of metastasis. In particular, CFHR5 was associated with the risk of metastasis. The role of circulating proteins involved in metastatic progression will be crucial for a better understanding of STS biology and patient management.
Collapse
Affiliation(s)
- Amalia Conti
- Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.,Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Claudia Fredolini
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Davide Tamburro
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Giovanna Magagnoli
- Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
| | - Weidong Zhou
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Lance A Liotta
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Piero Picci
- Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
| | - Alessandra Luchini
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Maria Serena Benassi
- Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
| |
Collapse
|
10
|
Tang Z, Ma J, Zhang W, Gong C, He J, Wang Y, Yu G, Yuan C, Wang X, Sun Y, Ma J, Liu F, Zhao Y. The Role of Prion Protein Expression in Predicting Gastric Cancer Prognosis. J Cancer 2016; 7:984-90. [PMID: 27313789 PMCID: PMC4910591 DOI: 10.7150/jca.14237] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Accepted: 03/15/2016] [Indexed: 12/26/2022] Open
Abstract
Previous reports indicated that prion protein (PrP) is involved in gastric cancer (GC) development and progression, but its role in GC prognosis has been poorly characterized. A total of 480 GC patients were recruited in this retrospective study. PrP expression in cancerous and non-cancerous gastric tissues was detected by using the tissue microarray and immunohistochemical staining techniques. Our results showed that the PrP expression in GC was significantly less frequent than that in the non-cancerous gastric tissue (44.4% vs 66.4%, P < 0.001). Cox regression analysis revealed that PrP expression was associated with TNM stage, survival status and survival time. GC patients with higher TNM stages (stages II, III and IV) had significantly lower PrP expression levels in tumors than those with lower TNM stages (stages 0 and I). Kaplan-Meier survival curves revealed that negative PrP expression was associated with poor overall survival (log-rank test: P < 0.001). The mean survival time for patients with negative PrP expression was significant lower than those with positive PrP expression (43.0±28.5m vs. 53.9±31.1m, P<0.001). In multivariate Cox hazard regression, PrP expression was an independent prognostic factor for GC survival, with a HR (hazard ratio) of 0.687 (95%CI:0.520-0.907, P=0.008). Our results revealed that negative PrP expression could independently predict worse outcome in GC and thereby could be used to guide the clinical practice.
Collapse
Affiliation(s)
- Zhaoqing Tang
- 1. Department of General surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Ji Ma
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| | - Wei Zhang
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China;; 5. Department of Pathology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, P.R. China
| | - Changguo Gong
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| | - Jing He
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| | - Ying Wang
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China;; 3. Department of Physiology, Renji College, Wenzhou Medical University, Wenzhou, P.R. China
| | - Guohua Yu
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| | - Chonggang Yuan
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| | - Xuefei Wang
- 1. Department of General surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Yihong Sun
- 1. Department of General surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Jiyan Ma
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China;; 4. Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA
| | - Fenglin Liu
- 1. Department of General surgery, Zhongshan Hospital, Fudan University, Shanghai, P.R. China
| | - Yulan Zhao
- 2. School of Life Sciences, East China Normal University, Shanghai, P.R. China
| |
Collapse
|
11
|
Gil M, Kim YK, Kim KE, Kim W, Park CS, Lee KJ. Cellular prion protein regulates invasion and migration of breast cancer cells through MMP-9 activity. Biochem Biophys Res Commun 2016; 470:213-219. [PMID: 26778001 DOI: 10.1016/j.bbrc.2016.01.038] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Accepted: 01/07/2016] [Indexed: 02/07/2023]
Abstract
Function of cellular prion protein (PrP(c)) in cancer progression has not been elucidated yet. Ectopic expression of PrP(c) increases the invasion and migration of breast cancer cell line, MCF-7 cells. Overexpressed PrP(c) increases matrix metalloprotease-9 (MMP-9) expression by enhancing association of NF-κB in promoter of MMP-9 gene and ERK signaling in MCF-7 cells. Whereas, silencing of PrP(c) by siRNA suppresses ERK activation and MMP-9 expression resulting the down-regulation of MD-MB231 cell migration and invasion. Overall, these results suggest that PrP(c) contribute the breast cancer invasion and migration via MMP-9.
Collapse
Affiliation(s)
- Minchan Gil
- SIS Immunology Research Institute, Sookmyung Women's University, Seoul, South Korea
| | - Yun Kye Kim
- Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul 138-736, South Korea
| | - Kyung-Eun Kim
- SIS Immunology Research Institute, Sookmyung Women's University, Seoul, South Korea
| | - Wook Kim
- Department of Molecular Science and Technology, Ajou University, Suwon 443-749, South Korea
| | - Chan-Sik Park
- Department of Pathology, Cell Dysfunction Research Center, University of Ulsan College of Medicine, Seoul, South Korea.
| | - Kyung Jin Lee
- Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul 138-736, South Korea.
| |
Collapse
|
12
|
Yang X, Zhang Y, Zhang L, He T, Zhang J, Li C. Prion protein and cancers. Acta Biochim Biophys Sin (Shanghai) 2014; 46:431-40. [PMID: 24681883 DOI: 10.1093/abbs/gmu019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The normal cellular prion protein, PrP(C) is a highly conserved and widely expressed cell surface glycoprotein in all mammals. The expression of PrP is pivotal in the pathogenesis of prion diseases; however, the normal physiological functions of PrP(C) remain incompletely understood. Based on the studies in cell models, a plethora of functions have been attributed to PrP(C). In this paper, we reviewed the potential roles that PrP(C) plays in cell physiology and focused on its contribution to tumorigenesis.
Collapse
Affiliation(s)
- Xiaowen Yang
- Department of the First Abdominal Surgery, Jiangxi Tumor Hospital, Nanchang 330029, China
| | - Yan Zhang
- Department of Molecular Endocrinology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, China State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
| | - Lihua Zhang
- Department of Pathology, Zhongda Hospital, Southeast University, Nanjing 210009, China
| | - Tianlin He
- Department of General Surgery, Changhai Hospital of Second Military Medical University, Shanghai 200433, China
| | - Jie Zhang
- Department of Stomatology, The First Affiliated Hospital of Shihezi University Medical College, Shihezi 832000, China
| | - Chaoyang Li
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
| |
Collapse
|
13
|
Yu G, Jiang L, Xu Y, Guo H, Liu H, Zhang Y, Yang H, Yuan C, Ma J. Silencing prion protein in MDA-MB-435 breast cancer cells leads to pleiotropic cellular responses to cytotoxic stimuli. PLoS One 2012; 7:e48146. [PMID: 23133614 PMCID: PMC3487893 DOI: 10.1371/journal.pone.0048146] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Accepted: 09/20/2012] [Indexed: 01/18/2023] Open
Abstract
Prion protein (PrP) is well studied for its pathogenic role in prion disease, but its potential contribution to other pathological processes is less understood. PrP is expressed in a variety of cancers and at least in pancreatic and breast cancers, its expression appears to be associated with poor prognosis. To understand the role of PrP in breast cancer cells, we knocked down PrP expression in MDA-MB-435 breast cancer cells with small interfering RNA and subjected these cells to a series of analyses. We found that PrP knockdown in these cells does not affect cell proliferation or colony formation, but significantly influences the cellular response to cytotoxic stimuli. Compared to control cells, PrP knockdown cells exhibited an increased susceptibility to serum deprivation induced apoptosis, no change to staurosporine- or paclitaxel-induced cell deaths, and a reduced susceptibility to chemotherapy drug doxorubicin-induced cell death. To understand the mechanism of unexpected role of PrP in exacerbating doxorubicin-induced cytotoxicity, we analyzed cell death related Bcl-2 family proteins. We found that PrP knockdown alters the expression of several Bcl-2 family proteins, correlating with increased resistance to doxorubicin-induced cytotoxicity. Moreover, the enhanced doxorubicin resistance is independent of DNA damage related p53 pathway, but at least partially through the ERK1/2 pathway. Together, our study revealed that silencing PrP in MDA-MB-435 breast cancer cells results in very different responses to various cytotoxic stimuli and ERK1/2 signaling pathway is involved in PrP silencing caused resistance to doxorubicin.
Collapse
Affiliation(s)
- Guohua Yu
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
- * E-mail: (GY); (LJ); (JM)
| | - Liming Jiang
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
- * E-mail: (GY); (LJ); (JM)
| | - Yuanyuan Xu
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
| | - Hongwei Guo
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
| | - Huiyan Liu
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
| | - Yi Zhang
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
- Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio, United States of America
| | - Huaiyi Yang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
| | - Chonggang Yuan
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
| | - Jiyan Ma
- School of Life Sciences, Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, East China Normal University, Shanghai, China
- Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio, United States of America
- * E-mail: (GY); (LJ); (JM)
| |
Collapse
|